Rhythm Pharmaceuticals (RYTM) Common Equity (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Common Equity data on file, last reported at $122.9 million in Q1 2026.

• Common Equity for Q1 2026 came in at $122.9 million, up 548.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $122.9 million (up 548.68% YoY), and the FY2025 annual result was $139.1 million, up 540.02% from the prior year.
• Common Equity retreated to $122.9 million in Q1 2026 per RYTM's latest filing, from $139.1 million in the prior quarter.
• Over five years, Common Equity peaked at $281.2 million in Q3 2022 and troughed at -$11.9 million in Q2 2025.
• A 5-year average of $135.2 million and a median of $148.8 million in 2025 frame the typical range for Common Equity.
• On a YoY basis, Common Equity climbed as much as 1226.95% in 2025 and fell as far as 130.27% in 2025.
• A 5-year view of Common Equity shows it stood at $264.3 million in 2022, then tumbled by 35.76% to $169.8 million in 2023, then plunged by 87.2% to $21.7 million in 2024, then jumped by 540.02% to $139.1 million in 2025, then decreased by 11.62% to $122.9 million in 2026.
• Business Quant data shows RYTM's Common Equity at $122.9 million in Q1 2026, $139.1 million in Q4 2025, and $148.8 million in Q3 2025.